Archon Partners LLC Makes New $11.16 Million Investment in Becton, Dickinson and Company $BDX

Archon Partners LLC acquired a new position in shares of Becton, Dickinson and Company (NYSE:BDX) during the first quarter, Holdings Channel.com reports. The fund acquired 71,000 shares of the medical instruments supplier’s stock, valued at approximately $11,163,000. Becton, Dickinson and Company accounts for approximately 1.3% of Archon Partners LLC’s holdings, making the stock its 27th largest holding.

Other large investors have also recently bought and sold shares of the company. Waverly Advisors LLC boosted its stake in Becton, Dickinson and Company by 108.2% during the first quarter. Waverly Advisors LLC now owns 17,640 shares of the medical instruments supplier’s stock valued at $2,774,000 after buying an additional 9,166 shares during the period. Healthcare of Ontario Pension Plan Trust Fund boosted its stake in Becton, Dickinson and Company by 57.8% in the first quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 17,884 shares of the medical instruments supplier’s stock worth $2,812,000 after buying an additional 6,554 shares in the last quarter. Dai ichi Life Insurance Company Ltd grew its holdings in shares of Becton, Dickinson and Company by 7.7% during the 1st quarter. Dai ichi Life Insurance Company Ltd now owns 25,159 shares of the medical instruments supplier’s stock valued at $3,956,000 after purchasing an additional 1,796 shares during the last quarter. Gabelli Funds LLC grew its stake in shares of Becton, Dickinson and Company by 6.1% during the first quarter. Gabelli Funds LLC now owns 47,003 shares of the medical instruments supplier’s stock valued at $7,390,000 after buying an additional 2,708 shares during the last quarter. Finally, Hilltop Holdings Inc. bought a new position in Becton, Dickinson and Company during the 1st quarter worth approximately $277,000. 86.97% of the stock is owned by institutional investors.

Becton, Dickinson and Company Stock Up 2.2%

BDX opened at $156.26 on Friday. The company has a quick ratio of 0.55, a current ratio of 0.94 and a debt-to-equity ratio of 0.62. The firm has a 50 day moving average price of $149.95 and a 200-day moving average price of $164.97. Becton, Dickinson and Company has a twelve month low of $127.59 and a twelve month high of $187.35. The stock has a market capitalization of $43.06 billion, a price-to-earnings ratio of 39.56, a PEG ratio of 11.06 and a beta of 0.21.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.77 by $0.13. Becton, Dickinson and Company had a net margin of 5.33% and a return on equity of 15.37%. The company had revenue of $4.71 billion for the quarter, compared to analysts’ expectations of $4.67 billion. During the same quarter last year, the company posted $3.35 earnings per share. The firm’s quarterly revenue was up 5.2% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. Equities research analysts forecast that Becton, Dickinson and Company will post 12.62 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, June 30th. Stockholders of record on Tuesday, June 9th were paid a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date was Tuesday, June 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 106.33%.

Analyst Ratings Changes

Several brokerages have recently issued reports on BDX. Wells Fargo & Company raised their target price on shares of Becton, Dickinson and Company from $157.00 to $161.00 and gave the stock an “equal weight” rating in a report on Friday, May 8th. Piper Sandler reduced their price target on shares of Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating on the stock in a research report on Friday, April 17th. Barclays increased their price objective on Becton, Dickinson and Company from $202.00 to $204.00 and gave the stock an “overweight” rating in a report on Monday, May 11th. Bank of America decreased their target price on shares of Becton, Dickinson and Company from $177.00 to $170.00 in a research note on Friday, June 12th. Finally, Weiss Ratings lowered Becton, Dickinson and Company from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, May 11th. Seven investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $180.29.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,100 shares of the firm’s stock in a transaction dated Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total value of $160,226.00. Following the transaction, the executive vice president directly owned 13,172 shares of the company’s stock, valued at approximately $1,918,633.52. This trade represents a 7.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 2,764 shares of the business’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $146.35, for a total value of $404,511.40. Following the sale, the chief executive officer owned 110,163 shares of the company’s stock, valued at approximately $16,122,355.05. This represents a 2.45% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 5,188 shares of company stock valued at $765,120 in the last ninety days. 0.40% of the stock is currently owned by corporate insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.